search

Active clinical trials for "Meningeal Neoplasms"

Results 1-10 of 16

Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/...

Leptomeningeal Disease

To determine the safety of intrathecal (IT) PD1 antibody for Intrathecal application of PD1 antibody in metastatic solid tumors with leptomeningeal disease of solid tumors.

Recruiting32 enrollment criteria

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

Leptomeningeal DiseaseTriple Negative Breast Cancer1 more

The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), to find the highest dose of the study treatment that can be given safely to Breast Cancer patients with Leptomeningeal Disease

Recruiting29 enrollment criteria

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal...

HER2-positive Breast CancerLeptomeningeal Metastasis1 more

The purpose of this study is to find out if radiation therapy followed by intrathecal trastuzumab and pertuzumab is safe and will result in improved survival in HER2 positive breast cancer which has metastasized to the leptomeninges.

Recruiting23 enrollment criteria

Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

Leptomeningeal MetastasesLeptomeningeal Disease

This study is to find a safe dose of the combination of Avelumab and Whole Brain Radiotherapy (WBRT) in patients with Leptomeningeal Disease.

Active41 enrollment criteria

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Acral Lentiginous MelanomaCentral Nervous System Melanoma8 more

This phase I/Ib trial studies the side effects and best dose of intrathecal nivolumab, and how well it works in combination with intravenous nivolumab in treating patients with leptomeningeal disease. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Active54 enrollment criteria

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced...

Leptomeningeal NeoplasmMetastatic Lung Non-Small Cell Carcinoma5 more

This phase I/Ib trial studies the side effects and best dose of CB-839 HCl when given together with sapanisertib in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). CB-839 HCl and sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Suspended56 enrollment criteria

Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology

Central Nervous System NeoplasmLeptomeningeal Neoplasm2 more

This study evaluates patient perceptions around quality of care through telemedicine in neuro-oncology. Studying questionnaires related to perceptions quality of care through telemedicine in patients with brain cancer may help doctors to improve the delivery of care through this modality.

Recruiting8 enrollment criteria

Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

Non-small Cell Lung CancerLeptomeningeal Disease1 more

Brain metastases occurs in up to 50% of patients with EGFR mutant NSCLC. Leptomeningeal disease is a subset of patients with brain metastases for which there remains an unmet need. This trial aims to evaluate the role of two dosing schedules of afatinib in management of leptomeningeal disease in EGFR mutant NSCLC, specifically to determine Central Nervous System (CNS) penetration of afatinib, as well as clinical activity. Patients will start on daily dosing initially followed by pulsed intermittent dosing should we observe no clinical activity. A secondary objective is to identify the resistance spectrum in leptomeningeal disease. It is anticipated that optimal dosing schedule of afatinib e.g. pulsed dosing may improve CNS disease control.

Terminated25 enrollment criteria

Pembrolizumab in Patients With Leptomeningeal Disease

Patients With Leptomeningeal Disease

This is an open-label phase II study of pembrolizumab in patients with advanced solid tumors with leptomeningeal carcinomatosis (LMD). Approximately 18 subjects in this study will receive pembrolizumab at a dose of 200mg intravenously (IV) every 3 weeks (Q3W) for 4 doses.

Terminated45 enrollment criteria

S9624 Ifosfamide in Treating Patients With Meningeal Tumors

ChondrosarcomaAdult Fibrosarcoma4 more

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ifosfamide in treating patients with meningeal tumors that have recurred or that cannot be removed surgically.

Terminated60 enrollment criteria
12

Need Help? Contact our team!


We'll reach out to this number within 24 hrs